Few and Far Between: How HIV May Be Evading Antibody Avidity

1. Rerks-NgarmS

PitisuttithumP

NitayaphanS

KaewkungwalJ

ChiuJ

2009 Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361 2209 2220

2. DolinR

2009 HIV vaccine trial results–an opening for further research. N Engl J Med 361 2279 2280

3. KoupRA

SafritJT

CaoY

AndrewsCA

McLeodG

1994 Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68 4650 4655

4. MiguelesSA

SabbaghianMS

ShupertWL

BettinottiMP

MarincolaFM

2000 HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 97 2709 2714

5. McMichaelAJ

Rowland-JonesSL

2001 Cellular immune responses to HIV. Nature 410 980 987

6. WeiX

DeckerJM

WangS

HuiH

KappesJC

2003 Antibody neutralization and escape by HIV-1. Nature 422 307 312

7. KwongPD

DoyleML

CasperDJ

CicalaC

LeavittSA

2002 HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420 678 682

8. LabrijnAF

PoignardP

RajaA

ZwickMB

DelgadoK

2003 Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 77 10557 10565

9. KwongPD

WyattR

RobinsonJ

SweetRW

SodroskiJ

1998 Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 648 659

10. WyattR

DesjardinE

OlshevskyU

NixonC

BinleyJ

1997 Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein. J Virol 71 9722 9731

11. MooreJP

SodroskiJ

1996 Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 70 1863 1872

12. StarcichBR

HahnBH

ShawGM

McNeelyPD

ModrowS

1986 Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 45 637 648

13. XiaoX

ChenW

FengY

ZhuZ

PrabakaranP

2009 Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun 390 404 409

14. RossmannMG

1989 The canyon hypothesis. Hiding the host cell receptor attachment site on a viral surface from immune surveillance. J Biol Chem 264 14587 14590

15. KwongPD

WilsonIA

2009 HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol 10 573 578

16. SkehelJJ

StevensDJ

DanielsRS

DouglasAR

KnossowM

1984 A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci U S A 81 1779 1783

17. PlotkinSA

2008 Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 47 401 409

18. Karlsson HedestamGB

FouchierRA

PhogatS

BurtonDR

SodroskiJ

2008 The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6 143 155

19. KleinJS

2009 Investigations in the design and characterization of HIV-1 neutralizing molecules. Pasadena California Institute of Technology. 166

20. JanewayCA

TraversP

WalportM

SchlomchikMJ

2005 Immunobiology. New York, , NY Garland Science Publishing

21. ScheidJF

MouquetH

FeldhahnN

SeamanMS

VelinzonK

2009 Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458 636 640

22. TomarasGD

YatesNL

LiuP

QinL

FoudaGG

2008 Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82 12449 12463

23. MattesMJ

2005 Binding parameters of antibodies: pseudo-affinity and other misconceptions. Cancer Immunol Immunother 54 513 516

24. SmithTJ

OlsonNH

ChengRH

ChaseES

BakerTS

1993 Structure of a human rhinovirus-bivalently bound antibody complex: implications for viral neutralization and antibody flexibility. Proc Natl Acad Sci U S A 90 7015 7018

25. IcenogleJ

ShiwenH

DukeG

GilbertS

RueckertR

1983 Neutralization of poliovirus by a monoclonal antibody: kinetics and stoichiometry. Virology 127 412 425

26. ZhangMY

XiaoX

SidorovIA

ChoudhryV

ChamF

2004 Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol 78 9233 9242

27. KleinJS

GnanapragasamPN

GalimidiRP

FoglesongCP

WestAPJr

2009 Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc Natl Acad Sci U S A 106 7385 7390

28. OfekG

TangM

SamborA

KatingerH

MascolaJR

2004 Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 78 10724 10737

29. KunertR

WolbankS

StieglerG

WeikR

KatingerH

2004 Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses 20 755 762

30. WolbankS

KunertR

StieglerG

KatingerH

2003 Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J Virol 77 4095 4103

31. SchofieldDJ

StephensonJR

DimmockNJ

1997 Variations in the neutralizing and haemagglutination-inhibiting activities of five influenza A virus-specific IgGs and their antibody fragments. J Gen Virol 78 (Pt 10) 2431 2439

32. WuH

PfarrDS

TangY

AnLL

PatelNK

2005 Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 350 126 144

33. EdwardsMJ

DimmockNJ

2001 Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event. J Virol 75 10208 10218

34. PantaleoG

KoupRA

2004 Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 10 806 810

35. YamaguchiM

DanevR

NishiyamaK

SugawaraK

NagayamaK

2008 Zernike phase contrast electron microscopy of ice-embedded influenza A virus. J Struct Biol 162 271 276

36. BachmannMF

ZinkernagelRM

1996 The influence of virus structure on antibody responses and virus serotype formation. Immunol Today 17 553 558

37. ZhuP

ChertovaE

BessJJr

LifsonJD

ArthurLO

2003 Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci U S A 100 15812 15817

38. ZhuP

LiuJ

BessJJr

ChertovaE

LifsonJD

2006 Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441 847 852

39. LiuJ

BartesaghiA

BorgniaMJ

SapiroG

SubramaniamS

2008 Molecular architecture of native HIV-1 gp120 trimers. Nature 455 109 113

40. ChertovaE

BessJWJr

CriseBJ

SowderIR

SchadenTM

2002 Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 76 5315 5325

41. LayneSP

MergesMJ

DemboM

SpougeJL

ConleySR

1992 Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 189 695 714

42. SougratR

BartesaghiA

LifsonJD

BennettAE

BessJW

2007 Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog 3 e63 doi:10.1371/journal.ppat.0030063

43. YangX

KurtevaS

RenX

LeeS

SodroskiJ

2005 Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J Virol 79 12132 12147

44. MagnusC

RusertP

BonhoefferS

TrkolaA

RegoesRR

2009 Estimating the stoichiometry of human immunodeficiency virus entry. J Virol 83 1523 1531

45. McInerneyTL

McLainL

ArmstrongSJ

DimmockNJ

1997 A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event. Virology 233 313 326

46. YuX

YuanX

MatsudaZ

LeeTH

EssexM

1992 The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol 66 4966 4971

47. BhatiaAK

KaushikR

CampbellNA

PontowSE

RatnerL

2009 Mutation of critical serine residues in HIV-1 matrix result in an envelope incorporation defect which can be rescued by truncation of the gp41 cytoplasmic tail. Virology 384 233 241

48. LuftigMA

MattuM

Di GiovineP

GeleziunasR

HrinR

2006 Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat Struct Mol Biol 13 740 747

49. ScanlanCN

PantophletR

WormaldMR

Ollmann SaphireE

StanfieldR

2002 The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1–>2 mannose residues on the outer face of gp120. J Virol 76 7306 7321

50. HessellAJ

RakaszEG

PoignardP

HangartnerL

LanducciG

2009 Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5 e1000433 doi:10.1371/journal.ppat.1000433

51. WestAPJr

GalimidiRP

FoglesongCP

GnanapragasamPN

Huey-TubmanKE

2009 Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency. J Virol 83 98 104

52. WalkerLM

PhogatSK

Chan-HuiPY

WagnerD

PhungP

2009 Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326 285 289

53. BonginiL

FanelliD

PiazzaF

De Los RiosP

SannerM

2007 A dynamical study of antibody-antigen encounter reactions. Phys Biol 4 172 180

54. StamatatosL

MorrisL

BurtonDR

MascolaJR

2009 Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 15 866 870

55. PantophletR

WilsonIA

BurtonDR

2004 Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. Protein Eng Des Sel 17 749 758

56. BurtonDR

StanfieldRL

WilsonIA

2005 Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A 102 14943 14948

57. PantophletR

BurtonDR

2006 GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24 739 769

58. ChanDC

FassD

BergerJM

KimPS

1997 Core structure of gp41 from the HIV envelope glycoprotein. Cell 89 263 273

59. WeissenhornW

DessenA

HarrisonSC

SkehelJJ

WileyDC

1997 Atomic structure of the ectodomain from HIV-1 gp41. Nature 387 426 430

60. KwongPD

WyattR

MajeedS

RobinsonJ

SweetRW

2000 Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 8 1329 1339

61. ChenB

VoganEM

GongH

SkehelJJ

WileyDC

2005 Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433 834 841

62. HuangCC

TangM

ZhangMY

MajeedS

MontabanaE

2005 Structure of a V3-containing HIV-1 gp120 core. Science 310 1025 1028

63. HuangCC

LamSN

AcharyaP

TangM

XiangSH

2007 Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317 1930 1934

64. ZhouT

XuL

DeyB

HessellAJ

Van RykD

2007 Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445 732 737

65. ChenL

KwonYD

ZhouT

WuX

O'DellS

2009 Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326 1123 1127

66. DiskinR

MarcovecchioPM

BjorkmanPJ

2010 Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nat Struct Mol Biol. doi:10.1038/nsmb.1796

67. ZanettiG

BriggsJA

GrunewaldK

SattentauQJ

FullerSD

2006 Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog 2 e83 doi:10.1371/journal.ppat.0020083

68. BennettA

LiuJ

Van RykD

BlissD

ArthosJ

2007 Cryoelectron tomographic analysis of an HIV-neutralizing protein and its complex with native viral gp120. J Biol Chem 282 27754 27759

69. SaphireEO

ParrenPW

PantophletR

ZwickMB

MorrisGM

2001 Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293 1155 1159

70. CrooksET

JiangP

FrantiM

WongS

ZwickMB

2008 Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. Virology 377 364 378

71. ZinglerK

LittmanDR

1993 Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases env incorporation into particles and fusogenicity and infectivity. J Virol 67 2824 2831

72. JohnstonPB

DubayJW

HunterE

1993 Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells. J Virol 67 3077 3086